Global Diabetic Retinopathy Market provides a brief and detailed knowledge about key players, market state and circumstances that are covered deeply in this report. The business chain supporting the Diabetic Retinopathy market is analysed in detail covering accurate information about aspects such as the industrial chain, proficiency in utilization of the available capacity of manufacture, and industry strategies that affect the market.
Diabetic Retinopathy Market
study offers an exhaustive summary of the vendor landscape, competitive
analysis, and key strategies to gain ruthless advantage. Diabetic Retinopathy
Market Forecast provides sizing and growth opportunities. It provides
comprehensive insights on the latest industry trends, forecast, and growth
drivers in the market. it also includes a detailed analysis of growth drivers,
challenges, and investment opportunities and delivers a complete overview of
segments and the regional outlook of the market.
Get Free PDF Sample (Including Full TOC,
List of Tables & Figures) @ https://www.millioninsights.com/industry-reports/diabetic-retinopathy-market/request-sample
The global Diabetic Retinopathy Market size is likely to reach USD 10.08 billion by 2025. Diabetes is a chronic disorder related with defects in the secretion of insulin from the hyperglycemia or pancreas associated to insulin resistance which eventually leads to long term multi-organ problems of kidneys, eye, blood vessels, nerves and heart.
Factors, such as increasing
aged population, up-gradation of healthcare infrastructure, rising demand for
initial detection systems, technological advancements, uncontrolled glucose
levels and ignorance towards treatment, and increasing research activities towards
developing advanced products are likely to drive the diabetic retinopathy
industry in the forthcoming period.
On the other hand, lack of
skilled professionals, presence of low-income groups, high cost associated with
the treatment and poor availability to healthcare services are anticipated to
hinder diabetic retinopathy market growth in future. However, prolonged
undiagnosed diabetes is likely to create lucrative opportunities for the
market. Diabetic retinopathy industry is anticipated to expand at a CAGR of
6.3% in the upcoming period as the scope, product types and its applications
are increasing across the globe.
Diabetic retinopathy market
is segmented by type, treatment type, indications, end user and geography. The
market is segmented by type as Proliferative Diabetic Retinopathy and
Non-proliferative diabetic retinopathy. The “Non-proliferative diabetic
retinopathy” segment accounted for a prominent share in the market. It is
likely to witness substantial growth in the years to come. The key factors that
could be attributed to the growth of market includes presence of huge number of
patients (less than 10 years of diabetic history) and increased occurrence of
diabetes.
Based on treatment type,
the diabetic retinopathy industry is segmented by Vitrectomy, Steroid Implants,
Anti VEGF Drug and Laser Surgeries. The “Anti VEGF Drug” segment accounted for
a prominent share in the market. It is likely to witness a substantial growth
in the years to come. The key factors that is could be attributed to the growth
of market include mild to moderate cases of non-proliferative DR treatment, and
better treatment and high applicability and faster recovery of these drugs in
treatment of initial diagnosis.
The diabetic retinopathy
market is segmented based on the end user as Ambulatory Surgical Centers,
Hospitals and Ophthalmic Clinics. Based on indications, the market of diabetic
retinopathy is segmented as Proliferative Diabetic Retinopathy (PDR) and
Non-Proliferative Diabetic Retinopathy (NPDR) (Severe, Moderate and Mild).
North America is a leading
region in the market. It is likely to maintain a dominance in the forecast
period owing to factors, such as a large number of aged populations, increase
in occurrence of diabetic retinopathy patients in the region, increasing
healthcare infrastructure and rising health awareness among population. In
addition, North America is followed by Asia-Pacific region owing to changing
lifestyle of people in the region, surge in diabetic population, increase in
funding and support provided by the government.
Key players operating in
the diabetic retinopathy industry include Alimera Science, Abbott Laboratories,
Allergan plc, Bayer AG, Ampio Pharmaceuticals., Novartis International AG, F.
Hoffmann-La Roche, Pfizer, Valeant Pharmaceutical, Regeneron Pharmaceuticals
Inc., KOWA Company, Ltd., Boehringer Ingelheim GmbH, ThromboGenics NV., and BCN
Peptides S.A. The leading companies are involved in partnerships, mergers and
acquisitions, and joint ventures in order to boost the inorganic growth of the
industry.
Know More Insights
@ https://newsonmarketblog.wordpress.com
No comments:
Post a Comment